Ray Dalio
RPRX icon

Ray Dalio’s Royalty Pharma RPRX Stock Holding History

Ray Dalio’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-49,416
Closed -$1.26M – 780
2024
Q4 		$1.26M Buy
+49,416
New +$1.31M 0.01% 483
2024
Q3 		– Sell
-238,991
Closed -$6.3M – 905
2024
Q2 		$6.3M Sell
238,991
-132,471
-36% -$3.67M 0.03% 316
2024
Q1 		$11.3M Buy
371,462
+350,314
+1,656% +$10.3M 0.06% 237
2023
Q4 		$594K Sell
21,148
-172,028
-89% -$4.73M ﹤0.01% 690
2023
Q3 		$5.24M Buy
193,176
+80,538
+72% +$2.39M 0.03% 357
2023
Q2 		$3.46M Buy
112,638
+79,201
+237% +$2.68M 0.02% 379
2023
Q1 		$1.2M Sell
33,437
-5,656
-14% -$210K 0.01% 539
2022
Q4 		$1.54M Sell
39,093
-22,759
-37% -$950K 0.01% 573
2022
Q3 		$2.48M Buy
61,852
+56,543
+1,065% +$2.42M 0.01% 515
2022
Q2 		$223K Sell
5,309
-35,178
-87% -$1.44M ﹤0.01% 966
2022
Q1 		$1.58M Buy
40,487
+34,739
+604% +$1.36M 0.01% 726
2021
Q4 		$229K Buy
+5,748
New +$223K ﹤0.01% 716
2021
Q3 		– Sell
-18,347
Closed -$752K – 782
2021
Q2 		$752K Buy
+18,347
New +$780K ﹤0.01% 614
2021
Q1 		– Sell
-13,535
Closed -$677K – 587
2020
Q4 		$677K Buy
+13,535
New +$574K 0.01% 432

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Ray Dalio's RPRX Position: Q1 2025 in Review

Ray Dalio sold out of Royalty Pharma (RPRX) in Q1 2025, closing a stake of 49,416 shares — an estimated $1.26M sold.

Ray Dalio first reported a position in RPRX in Q4 2020 and held it in 14 quarters. The position peaked at $11.3M in Q1 2024. 447 funds tracked by Wall St. Rank hold RPRX as of Q1 2025.

  • Ray Dalio reported no remaining Royalty Pharma position as of Q1 2025 after selling out during the quarter.
  • Ray Dalio sold 49,416 Royalty Pharma shares in Q1 2025, an estimated $1.26M.
  • Ray Dalio first reported a position in Royalty Pharma in Q4 2020 and held it in 14 quarters.
  • Ray Dalio's Royalty Pharma position peaked at $11.3M in Q1 2024.
  • 447 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2025.

Based on Bridgewater Associates's 13F filing for Q1 2025, filed 14 May 2025.